Vimarsana
Biggest News Aggregation in the World

Page 29 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Infrastructure bill, Russia issues keep lobbying revenues high - Vimarsana News

Infrastructure bill, Russia issues keep lobbying revenues high

Some in the industry expected lobbying spending to level out ahead of the midterms and after numerous pandemic relief bills and the initial burst that a new administration provides.

Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial | Neurology | JAMA - Vimarsana News

Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial | Neurology | JAMA

This randomized clinical trial compares the efficacy and adverse effects of the 3 most frequently prescribed corticosteroid regimens for boys with Duchenne musc

Global Pharma, Biotech & Diagnostics Co-promotion and Co-marketing Deals Report 2021: Comprehensive Access and Analysis of 350+ Deals - Vimarsana News

Global Pharma, Biotech & Diagnostics Co-promotion and Co-marketing Deals Report 2021: Comprehensive Access and Analysis of 350+ Deals

/PRNewswire/ -- The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2021" report has been added to...

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth - Vimarsana News

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use...

Shifting from megamergers to strategic collaboration: M&A in biopharma - Vimarsana News

Shifting from megamergers to strategic collaboration: M&A in biopharma

Will 2021's trend of high volume but small value merger and acquisition (M&A) deals continue in 2022? Subin Baral, EY Global Life Sciences Deals Leader discusses what is motivating the recent changes in M&A contracts.